16 November 2020
Netanya, Israel, November 16, 2020
Netanya, Israel. Trobix Innovation Ltd. (Trobix Bio), an Israeli-based biotechnology company developing therapies to remove the threat of antimicrobial resistance, announces that the company has emerged as a Top 100 Global #Startup of #SLINGSHOT2020, Asia’s most exciting #deeptech #startup competition!
After battling with more than 7,500 global startups, the Top 100 have been shortlisted and will be undergoing the #SLINGSHOT 100: #GearUp in preparation for the Virtual Finals at #SFFxSWITCH 2020 this December.
About Trobix Bio
Trobix Bio is a preclinical biotechnology company, developing therapies to remove the threat of antimicrobial resistance, a global crisis strongly evidenced nowadays during the COVID-19 Pandemic. Trobix Bio leverages its ActiSense™ and GoTrap™ technologies to develop phage-based products that can effectively deliver DNA to a wide range of bacterial pathogens, and actively sensitize these pathogens to antibiotics. The company’s lead product, TBX101, aims to treat patients carrying gut antimicrobial resistant bacteria, resulting in an antibiotic sensitive gut microbiome. Trobix Bio’s precision medicine technology minimizes resistance development to TBX101.
Don’t forget to sign up for SLINGSHOT @ SWITCH 2020 happening from 7 to 11 December 2020 and watch 100 Global Startups pitch live on a global stage.
@Enterprise Singapore @Startup SG